Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00262470 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treatment of Orthostatic Intolerance

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Dec 2027 to Dec 2029
    • Study description expanded, about 62 words
    v26
  2. Primary and study completion dates: Dec 2025 to Dec 2027v25
  3. Collaborator revisedv24
  4. Re-verified, no change to tracked fieldsv23
  5. Primary and study completion dates: Dec 2022 to Dec 2025v22
Show 20 earlier versionsHide 20 earlier versions
  1. Re-verified, no change to tracked fieldsv21
  2. Primary and study completion dates: Dec 2021 to Dec 2022v20
  3. Re-verified, no change to tracked fieldsv19
  4. Primary completion date: Jan 2018 to Dec 2021
    • Study completion date: Dec 2021
    v18
  5. Re-verified, no change to tracked fieldsv17
  6. Primary completion date: Jan 2016 to Jan 2018
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v16
  7. Primary completion date: Jan 2014 to Jan 2016
    • Interventions: Abdominal binder (Device), Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Baseline (No Drug) (Other)… to Abdominal binder (Device), Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Breathing Device (Device), Clonidine…
    v15
  8. Lead sponsor: Vanderbilt University to Satish R. Raj
    • Interventions: Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Baseline (No Drug) (Other), Breathing Device (Device)… to Abdominal binder (Device), Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Baseline (No Drug) (Other)…
    • Publications: 7 to 8
    • Study arms: 19 to 20
    v14
  9. Primary completion date: Jan 2013 to Jan 2014
    • Collaborator revised
    v13
  10. Re-verified, no change to tracked fieldsv12
  11. Primary completion date: Jan 2011 to Jan 2013v11
  12. 4 versions Re-verified since Jun 2, 2008, no change to tracked fieldsv7-v10
  13. Primary completion date: Jan 2011
    • Interventions: Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Baseline (No Drug) (Drug), Breathing Device (Procedure)… to Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Baseline (No Drug) (Other), Breathing Device (Device)…
    • Study arms: 0 to 19
    v6
  14. Interventions: Aprepitant (Drug), Aprepitant and 16 oz of Water (Drug), Atomoxetine (Drug), Baclofen (Drug), Baseline (No Drug) (Drug), Carbidopa (Drug)… to Acetazolamide (Drug), Atomoxetine & Propranolol (Drug), Atomoxetine (Drug), Baseline (No Drug) (Drug), Breathing Device (Procedure)…
    • Secondary endpoints: details revised at 5 of 5 entries
    v5
  15. Study completion date: Aug 2005 to not stated
    • Secondary endpoints revised (5)
    • Primary endpoint revised
    v4
  16. 2 versions Re-verified since Sep 6, 2006, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial is designed to study the effects of various mechanistically unique medications in controlling excessive increases in heart rate with standing and in improving the symptoms of orthostatic intolerance in patients with this disorder.
Trial Details
NCT Number NCT00262470
Lead Sponsor Satish R. Raj
Collaborators: National Center for Advancing Translational Sciences (NCATS)
Conditions
(from sponsor)		 Tachycardia, Chronic Orthostatic Intolerance
Related terms Postural Orthostatic Tachycardia Syndrome, Tachycardia, Tachycardia, Sinus
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov